Constellation Pharmaceuticals to Present at 36th Annual JP Morgan Healthcare Conference
CAMBRIDGE, Massachusetts, January 3, 2018 – Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing tumor-targeted and immuno-oncology therapies based on its pioneering research in cancer epigenetics, today announced that President and Chief Executive Officer Jigar Raythatha will present a company overview at the 36th Annual JP Morgan Healthcare Conference on January 11 at 11:00 a.m. PST (2:00 p.m. EST), in room Elizabethan D. The conference is being held January 8-11 at the Westin St. Francis in San Francisco, California.
About Constellation Pharmaceuticals
Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel small molecule therapies based on its pioneering research in cancer epigenetics. With a decade of experience in the field, the company has an unparalleled understanding of how epigenetic regulators modulate gene expression in cancer cells and in the tumor and immune microenvironment. Constellation is translating these insights to advance the company’s two lead clinical programs, CPI-1205 and CPI-0610, and in novel targets for which cancer epigenetics may help overcome resistance mechanisms to currently available treatment options.
For more information, please visit www.constellationpharma.com.
+1 (910) 509-3977
Stern Investor Relations, Inc.
+1 (212) 362-1200